Stryker Co. (NYSE:SYK) Stake Cut by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,397 shares of the medical technology company's stock after selling 832 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Stryker were worth $25,347,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Stryker during the 4th quarter worth about $1,710,744,000. Raymond James Financial Inc. bought a new stake in shares of Stryker in the 4th quarter valued at approximately $353,394,000. FMR LLC increased its holdings in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after buying an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after buying an additional 595,061 shares during the last quarter. Finally, Northern Trust Corp raised its position in Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on SYK shares. Canaccord Genuity Group increased their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Stifel Nicolaus increased their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Roth Mkm raised their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company boosted their price target on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus target price of $427.05.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.90% of the company's stock.

Stryker Price Performance

SYK opened at $389.30 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $148.59 billion, a P/E ratio of 50.17, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company's 50 day simple moving average is $367.75 and its 200-day simple moving average is $375.89.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter last year, the firm earned $2.50 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.